AU2015327762C1 - Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders - Google Patents

Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders Download PDF

Info

Publication number
AU2015327762C1
AU2015327762C1 AU2015327762A AU2015327762A AU2015327762C1 AU 2015327762 C1 AU2015327762 C1 AU 2015327762C1 AU 2015327762 A AU2015327762 A AU 2015327762A AU 2015327762 A AU2015327762 A AU 2015327762A AU 2015327762 C1 AU2015327762 C1 AU 2015327762C1
Authority
AU
Australia
Prior art keywords
rivastigmine
intranasal
formulation
disease
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015327762A
Other languages
English (en)
Other versions
AU2015327762B2 (en
AU2015327762A1 (en
Inventor
Timothy Matthias Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lachesis Biosciences Pty Ltd
Original Assignee
Lachesis Biosciences Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014903944A external-priority patent/AU2014903944A0/en
Application filed by Lachesis Biosciences Pty Ltd filed Critical Lachesis Biosciences Pty Ltd
Publication of AU2015327762A1 publication Critical patent/AU2015327762A1/en
Publication of AU2015327762B2 publication Critical patent/AU2015327762B2/en
Application granted granted Critical
Publication of AU2015327762C1 publication Critical patent/AU2015327762C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015327762A 2014-10-03 2015-09-30 Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders Active AU2015327762C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014903944A AU2014903944A0 (en) 2014-10-03 Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
AU2014903944 2014-10-03
PCT/AU2015/050591 WO2016049700A1 (en) 2014-10-03 2015-09-30 Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Publications (3)

Publication Number Publication Date
AU2015327762A1 AU2015327762A1 (en) 2017-04-20
AU2015327762B2 AU2015327762B2 (en) 2020-06-25
AU2015327762C1 true AU2015327762C1 (en) 2020-10-22

Family

ID=55629161

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015327762A Active AU2015327762C1 (en) 2014-10-03 2015-09-30 Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Country Status (12)

Country Link
US (3) US10471040B2 (enExample)
EP (1) EP3200828B1 (enExample)
JP (3) JP2017530195A (enExample)
AU (1) AU2015327762C1 (enExample)
CA (1) CA2961936C (enExample)
DK (1) DK3200828T3 (enExample)
ES (1) ES2822562T3 (enExample)
HU (1) HUE052441T2 (enExample)
PL (1) PL3200828T3 (enExample)
PT (1) PT3200828T (enExample)
SM (1) SMT202000576T1 (enExample)
WO (1) WO2016049700A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3200828T3 (pl) * 2014-10-03 2021-01-25 Lachesis Biosciences Limited Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych
LT3474850T (lt) * 2017-02-02 2020-08-10 Otolanum Ag Intranazalinė kompozicija, apimanti betahistiną
EP4171542A4 (en) * 2020-06-25 2024-07-24 Lachesis Biosciences Limited METHODS FOR TREATING OR PREVENTING ORGANOPHOSPHORUS POISONING
WO2022029604A1 (en) * 2020-08-07 2022-02-10 Council For Scientific And Industrial Research Microemulsion drug delivery system for treatment of acute respiratory distress syndrome
CA3193558A1 (en) * 2020-10-01 2022-04-07 Lyra Therapeutics, Inc. Osmotic drug delivery implants
CN115919767B (zh) * 2022-10-13 2023-08-11 暨南大学 卡巴拉汀鼻喷雾剂及其制备方法
CN119523898A (zh) * 2024-12-02 2025-02-28 肇庆学院 多靶点药物的经鼻给药制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US20060003989A1 (en) * 2002-05-21 2006-01-05 Nastech Pharmaceutical Company Inc. Compositions and methods using acetylcholinesterase (ACE) inhibitors to treat central nervous system (CNS) disorders in mammals

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5733M (enExample) 1966-09-27 1968-01-22
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
FR2722989B1 (fr) 1994-07-29 1997-05-30 Synthelabo Utilisation de l'ifenprodil et de ses enantiomeres pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques et des maladies neurodegeneratives centrales
US6558560B2 (en) * 2001-07-27 2003-05-06 Hewlett-Packard Company Method for the fabrication of electrical contacts
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EP2153824A1 (en) * 2004-09-27 2010-02-17 Sigmoid Pharma Limited Seamless multiparticulate formulations
US8058291B2 (en) * 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US8187570B1 (en) * 2005-01-04 2012-05-29 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
CN101325944B (zh) * 2005-10-11 2013-01-16 耶路撒冷希伯来大学伊萨姆研究开发公司 用于鼻部给药的组合物
AU2007212586A1 (en) * 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
AR059358A1 (es) * 2006-02-09 2008-03-26 Schering Corp Formulaciones farmaceuticas
US20100197811A1 (en) * 2007-06-26 2010-08-05 Hidekazu Suzuki Aqueous composition
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
KR20180101641A (ko) 2010-05-17 2018-09-12 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
US8673338B2 (en) * 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
PL3200828T3 (pl) * 2014-10-03 2021-01-25 Lachesis Biosciences Limited Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US20060003989A1 (en) * 2002-05-21 2006-01-05 Nastech Pharmaceutical Company Inc. Compositions and methods using acetylcholinesterase (ACE) inhibitors to treat central nervous system (CNS) disorders in mammals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WAVIKAR, P.R. et al. "Rivastigmine-loaded in situ gelling nanostructured lipid carriers for nose to brain delivery" Journal of Liposome Research (2015) Vol.25 No.2, pages 141 to 149 *

Also Published As

Publication number Publication date
AU2015327762B2 (en) 2020-06-25
JP2020090547A (ja) 2020-06-11
JP2017530195A (ja) 2017-10-12
AU2015327762A1 (en) 2017-04-20
EP3200828A1 (en) 2017-08-09
SMT202000576T1 (it) 2020-11-10
CA2961936C (en) 2023-03-14
CA2961936A1 (en) 2016-04-07
WO2016049700A1 (en) 2016-04-07
US11911360B2 (en) 2024-02-27
US20200078331A1 (en) 2020-03-12
ES2822562T3 (es) 2021-05-04
JP2022003100A (ja) 2022-01-11
US10471040B2 (en) 2019-11-12
US10933045B2 (en) 2021-03-02
DK3200828T3 (da) 2020-10-12
PL3200828T3 (pl) 2021-01-25
HUE052441T2 (hu) 2021-04-28
EP3200828A4 (en) 2018-04-25
US20170239209A1 (en) 2017-08-24
EP3200828B1 (en) 2020-08-12
PT3200828T (pt) 2020-10-08
US20210145789A1 (en) 2021-05-20
JP7357571B2 (ja) 2023-10-06

Similar Documents

Publication Publication Date Title
US11911360B2 (en) Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
Curran et al. Cetirizine: a review of its use in allergic disorders
JP2022088592A (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
AU2025210905A1 (en) Method of treatment with tradipitant
JP7502404B2 (ja) 眼の病状の治療方法
JP2014511382A (ja) フルマゼニル錯体、それを含む組成物、およびその使用
CA3101334A1 (en) Cannabis-based compositions for the treatment of autistic spectrum disorders
JP2022548233A (ja) エスケタミンの鼻腔内投与
US20240408054A1 (en) Compositions and methods for increasing exposure of r(-)-mda
Prakash et al. Novel anti-cholinergics in COPD
HUE031442T2 (en) Aclidinium for use in improving the quality of sleep in respiratory patients.
EP2825172B1 (en) Paralytic shellfish poison for the treatment of itch
WO2012098495A1 (en) Pharmaceutical composition that includes revamilast and a beta-2 agonist
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
EP3964215A1 (en) Pharmaceutical composition, comprising 6-diazo-5-oxo-l-norleucine, for treatment of inflammatory skin disease
US20230172895A1 (en) Methods of treating or preventing organophosphorus poisoning
WO2024234014A1 (en) Sublingual spray formulations of psychedelics
EP4003297A2 (en) New formulations of amisulpride
Aronson New antihistamines
US20190125734A1 (en) Composition for treating or preventing atopic dermatitis
WO2003101437A2 (en) Method of treating asthma using fexofenadine

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 16 JUN 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 16 JUN 2020

FGA Letters patent sealed or granted (standard patent)